Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant human endostatin - Simcere

Drug Profile

Recombinant human endostatin - Simcere

Alternative Names: Endostar; Endu; rh-endostatin; YH-16

Latest Information Update: 16 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Simcere Pharmaceutical Group
  • Developer Peking University; Simcere Pharmaceutical Group
  • Class Angiostatic proteins; Antineoplastics; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Gelatinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II/III Colorectal cancer
  • No development reported Brain metastases; Gastric cancer; Malignant ascites; Malignant melanoma; Malignant pleural effusion; Oesophageal cancer; Osteosarcoma; Small cell lung cancer

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Inoperable/Unresectable, Late-stage disease) in China (SC, Injection)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Aug 2015 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Inoperable/Unresectable) in China (SC) (NCT02652234)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top